Navigation Links
ProtoKinetix Partners with OTC Financial Network to Increase Shareholder Base
Date:10/14/2008

VANCOUVER, Canada, Oct. 14 /PRNewswire-FirstCall/ -- ProtoKinetix (OTC Bulletin Board: PKTX), a biotech company focused on the research, development and commercialization of patented anti-aging glycopeptides (AAGPs(TM)), announced today that it has partnered with OTC Financial Network (OTCFN), a division of National Financial Communications Corp. (NFC), to direct a comprehensive shareholder awareness campaign.

"ProtoKinetix' AAGP(TM) platform technology is ideal for a number of applications in the skin care/cosmetics, cellular therapy, blood preservation and pharmaceutical industries," said Geoffrey Eiten, president of NFC. "Last month, ProtoKinetix entered into its first licensing agreement to provide AAGP(TM) as the primary active ingredient in an anti-inflammatory cream for the sports injury market. This contract is one of several in the pipeline that position ProtoKinetix on a path to commercial success. We look forward to introducing the Company and its world-class management team to the financial community."

"We've selected to partner with OTCFN to increase our market awareness and widen our shareholder base," said Ross L. Senior, President and CEO of ProtoKinetix Inc. "We are excited to be working with a financial communications firm that has a well respected track record. We believe we can effectively enhance shareholder value by partnering with companies that offer the technical, marketing and distribution expertise to bring AAGP(TM) applications to market."

About OTC Financial Network

Since 1992, OTC Financial Network (OTCFN) has carved its niche as the nation's leading small/micro-cap investor relations and financial communications firm. OTCFN is a division of National Financial Communications Corp. (http://www.nationalfc.com) based in Needham, MA. For information, visit http://www.otcfn.com.

OTC Financial Network serves as special advisor to ProtoKinetix Inc. and has received fees for services, including two hundred and fifty-thousand shares of restricted stock, in addition to an option to purchase two-hundred fifty-thousand shares at an exercise price of twenty cents per share, for the creation and implementation of an awareness program. This is not an offer to buy or sell securities. Information or opinions in this release are presented solely for informative purposes, and are not intended nor should they be construed as investment advice. A full disclaimer can be found online by visiting http://www.otcfn.com/pktx/disclaimer.html.

About ProtoKinetix

ProtoKinetix, Inc. is a biotechnology company that has developed and patented a family of synthetic anti-aging glycopeptides (AAGP(TM)) for medicine and the biotechnology and cosmetic industries. PKTX is currently in dialog with major corporations and institutions who have contacted the Company about the broad range of applications for AAGP(TM) products. For more information, visit http://www.protokinetix.com.

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission.

CONTACT

Ross L. Senior, LLB - President and CEO

Company Office: Investor Contact:

Suite # 1500 ProtoKinetix Inc.

885 West Georgia Street 604-687-9887

Vancouver, BC V6C 3E8

At OTC Financial Network:

Rick McCaffrey

781-444-6100x625

rick@otcfn.com

http://www.otcfn.com/pktx


'/>"/>
SOURCE ProtoKinetix
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vista Partners Updates Coverage on Arana Therapeutics (ASX: AAH; AIM: AAHx), Raises Target Price to AU$1.65
2. Vista Partners Updates Coverage; Maintains $3.20 Target Price
3. Mentice, Inc. and Education Management Solutions, Inc. Form OEM Partnership
4. Creators of Britains Innovation Economy to Showcase the Technologies of the Future at the Fifth SETsquared Partnership Showcase 2008
5. Mirixa Corporation and the APhA Foundation Form Partnership
6. New Partnership Integrates Vibration Therapy Into Stem Cell Procedures
7. Samaritan Partners Forgetful Rat Model to Taconic to Commercialize
8. Lumiphore Partners with Biophor Diagnostics, Inc. to Develop Tests for Drugs of Abuse; Appoints Ibis Biosciences Founder David J. Ecker to Board
9. Riverside Partners Sells MicroCal to GE Healthcare
10. onTargetjobs and ClearedConnections Announce Online Recruitment Partnership
11. Water Street Health Care Partners Completes Agreement With Gentiva Health Services to Acquire Majority Ownership of CareCentrix
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016  Global demand for enzymes ... through 2020 to $7.2 billion.  This market includes ... cleaning products, biofuel production, animal feed, and other ... and biocatalysts). Food and beverages will remain the ... increasing consumption of products containing enzymes in developing ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... findings on what they believe could be a new and helpful biomarker for ... research. Click here to read it now. , Biomarkers are components ...
(Date:6/27/2016)... , ... June 27, 2016 , ... ... for Amgen, will join the faculty of the University of North Carolina ... professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the ...
(Date:6/24/2016)... , June 24, 2016  Regular discussions on a ... take place between the two entities said Poloz. ... Ottawa , he pointed to the country,s ... the federal government. ... said, "Both institutions have common economic goals, why not sit ...
Breaking Biology Technology:
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/26/2016)... 27, 2016 Research and ... Biometrics Market 2016-2020"  report to their offering.  , ... The analysts forecast the global multimodal biometrics ... during the period 2016-2020.  Multimodal biometrics ... such as the healthcare, BFSI, transportation, automotive, and ...
Breaking Biology News(10 mins):